Terms: = Leukemia AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Clinical Outcome
11 results:
1. Down-regulation of pseudogene Vimentin 2p is associated with poor outcome in de novo acute myeloid leukemia.
Zhai LL; Zhou J; Zhang J; Tang X; Zhou LY; Yin JY; Vanessa MD; Peng W; Lin J; Deng ZQ
Cancer Biomark; 2017; 18(3):305-312. PubMed ID: 28106537
[TBL] [Abstract] [Full Text] [Related]
2. CDH1 (E-cadherin) expression independently affects clinical outcome in acute myeloid leukemia with normal cytogenetics.
Zhang TJ; Zhou JD; Ma JC; Deng ZQ; Qian Z; Yao DM; Yang J; Li XX; Lin J; Qian J
Clin Chem Lab Med; 2017 Jan; 55(1):123-131. PubMed ID: 27305704
[TBL] [Abstract] [Full Text] [Related]
3. Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia.
Li Y; Lin J; Yang J; Qian J; Qian W; Yao DM; Deng ZQ; Liu Q; Chen XX; Xie D; An C; Tang CY
Leuk Res; 2013 Dec; 37(12):1642-7. PubMed ID: 24138945
[TBL] [Abstract] [Full Text] [Related]
4. RAS mutation analysis in a large cohort of Chinese patients with acute myeloid leukemia.
Yang X; Qian J; Sun A; Lin J; Xiao G; Yin J; Chen S; Wu D
Clin Biochem; 2013 May; 46(7-8):579-83. PubMed ID: 23313659
[TBL] [Abstract] [Full Text] [Related]
5. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia.
Shen Y; Zhu YM; Fan X; Shi JY; Wang QR; Yan XJ; Gu ZH; Wang YY; Chen B; Jiang CL; Yan H; Chen FF; Chen HM; Chen Z; Jin J; Chen SJ
Blood; 2011 Nov; 118(20):5593-603. PubMed ID: 21881046
[TBL] [Abstract] [Full Text] [Related]
6. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia.
Balgobind BV; Hollink IH; Arentsen-Peters ST; Zimmermann M; Harbott J; Beverloo HB; von Bergh AR; Cloos J; Kaspers GJ; de Haas V; Zemanova Z; Stary J; Cayuela JM; Baruchel A; Creutzig U; Reinhardt D; Pieters R; Zwaan CM; van den Heuvel-Eibrink MM
Haematologica; 2011 Oct; 96(10):1478-87. PubMed ID: 21791472
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic implication of n-ras gene mutations in Egyptian adult acute myeloid leukemia.
Elghannam DM; Abousamra NK; Shahin DA; Goda EF; Azzam H; Azmy E; El-Din MS; El-Refaei MF
Egypt J Immunol; 2009; 16(1):9-15. PubMed ID: 20726318
[TBL] [Abstract] [Full Text] [Related]
8. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.
Bowen DT; Frew ME; Hills R; Gale RE; Wheatley K; Groves MJ; Langabeer SE; Kottaridis PD; Moorman AV; Burnett AK; Linch DC
Blood; 2005 Sep; 106(6):2113-9. PubMed ID: 15951308
[TBL] [Abstract] [Full Text] [Related]
9. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).
Nanri T; Matsuno N; Kawakita T; Suzushima H; Kawano F; Mitsuya H; Asou N
Leukemia; 2005 Aug; 19(8):1361-6. PubMed ID: 15902284
[TBL] [Abstract] [Full Text] [Related]
10. Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia.
Kawamura M; Ohnishi H; Guo SX; Sheng XM; Minegishi M; Hanada R; Horibe K; Hongo T; Kaneko Y; Bessho F; Yanagisawa M; Sekiya T; Hayashi Y
Leuk Res; 1999 Feb; 23(2):115-26. PubMed ID: 10071127
[TBL] [Abstract] [Full Text] [Related]
11. n-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis.
Lübbert M; Mirro J; Miller CW; Kahan J; Isaac G; Kitchingman G; Mertelsmann R; Herrmann F; McCormick F; Koeffler HP
Blood; 1990 Mar; 75(5):1163-9. PubMed ID: 2407301
[TBL] [Abstract] [Full Text] [Related]
